Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors

Kiran H Clair; Nicolas Gallegos; Robert E Bristow

doi:10.1016/j.gore.2020.100625

Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors

Gynecol Oncol Rep. 2020 Sep 1:34:100625. doi: 10.1016/j.gore.2020.100625. eCollection 2020 Nov.

Authors

Kiran H Clair¹, Nicolas Gallegos², Robert E Bristow¹

Affiliations

¹ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Irvine Medical Center, Orange, CA, United States.
² Department of Pathology, University of California Irvine Medical Center, Orange, CA, United States.

Abstract

•Cure rates are high for choriocarcinoma, however chemoresistant disease often leads to death.•High expression of PD-L1 suggests a role for checkpoint inhibitors in choriocarcinoma.•Pembrolizumab should be considered for salvage therapy for chemoresistant choriocarcinoma.

Keywords: Chemotherapy resistance; Choriocarcinoma; Gestational trophoblastic neoplasia; Immunotherapy.

Publication types

Case Reports